Insulin-like Growth factor-I In Women Research Articles

Influence of a fermented protein-fortified dairy product on serum insulin-like growth factor-I in women with anorexia nervosa: A randomized controlled trial

Patients with anorexia nervosa (AN) have low serum IGF-I levels that may contribute to a lower bone mineral mass. We investigated the effects of a fermented, protein-fortified, dairy product on serum IGF-I levels in patients with AN during an in-hospital refeeding program. In this multicenter, randomized, double-blind, placebo-controlled, clinical trial conducted at 3 university hospitals and 3 private clinics in France and Switzerland, 62 women recently admitted with confirmed AN and with a baseline low serum IGF-I level were randomized to 2 daily isocaloric fresh cheese pots containing either 15g/150g or 3g/150g (controls) of protein for 4 weeks. The primary outcome was the change in IGF-I levels. In the primary intention-to-treat analysis, mean serum IGF-I levels increased during the intervention phase from 22.9±1.5 to 28.6±1.3nmol/L (means±SEM) (+20.2%) in the intervention group and from 20.2±1.2 to 25.7±1.5nmol/L (+16.8%) in controls. In a preplanned analysis of covariance with repeated measures, the between-group difference was close to statistical significance (P=0.071). In a post-hoc mixed-regression model analysis, the difference was statistically significant (4.9nmol/l increase; P=0.003), as was the change of the ratio IGF-I/IGF-BP3 (P=0.004). There was no between-group difference in biochemical markers of bone turnover (osteocalcin, P1NP, CTX) or in serum parathyroid hormone level. Serum calcium levels slightly increased during the intervention phase in the higher protein group (P=0.02). IGF-BP2 decreased significantly more in the intervention group during the follow up period at week 4 after supplements cessation (P=0.019). Intake of a fermented, protein-fortified, isocaloric dairy product during 4 weeks may slightly increase serum IGF-I levels in women with AN, without significant changes in bone turnover markers. NCT01823822 (www.clinicaltrials.gov).

Serum insulin-like growth factor-I adult reference values for an automated chemiluminescence immunoassay system

Analysis of insulin-like growth factor I (IGF-I) in serum is fundamental in order to aid in the diagnosis of growth hormone (GH)-related disorders, as well as in the diagnosis and follow-up of other diseases. Considering the importance of IGF-I local normal range, the aim of this study was to determine reference values for IGF-I (Immulite 2000) in a Brazilian adult population from the city of Rio de Janeiro. This study included samples of blood taken from 484 healthy subjects (251 men, 233 women) aged 18 to 70. The subjects agreed with this study, approved by the ethical committee of the Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil. The samples were analyzed by an automated immunochemiluminometric assay (ICMA). For data analysis, age and sex-specific figures were fitted after transformation of IGF-I values. In adulthood, a slow age-dependent decrease was seen. IGF-I in women were significantly higher than in men.The present study established age- and sexspecific IGF-I reference values, for the healthy Brazilian adult populatoin from the city of Rio de Janeiro, determined with the currently most widely IGF-I assay used in Brazil (Immulite 2000). Key words : Insulin-like growth factor I, chemiluminescence assay, reference range.

Serum and tissue levels of insulin-like growth factor-I in women with dysplasia and HPV-positive cervical cancer

The ectocervical epithelium is the target of the oncogenic human papillomavirus (HPV), which acts as an etiological agent in the development of cervical carcinoma. However, the HPV-mediated transformation of human epithelial cells is a multi-step process dependant on unknown factors additional to the virus, which is a necessary but, in and of itself, insufficient catalyst. In the present study, we characterized the role of insulin-like growth factor-I (IGF-I) in this process. IGF-I is an endocrine hormone with an autocrine and paracrine role in many tissues. Our data demonstrated that autocrine secretion of IGF-I can contribute to HPV-induced carcinogenesis of the epithelium. An immunohistochemical study showed that IGF-I was present in the nuclei of the reproductive layer of the paraepidermal epithelium in 89% of cases of intraepithelial neoplasia (CIN I-III) and 60% of cases of invasive cervical cancer. The presence of IGF-I at a nuclear localization in the cells studied suggests that it may also have intranuclear actions.

Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension

Objective: The purpose of this study was to assess insulin, insulin sensitivity, and insulin-like growth factor-I in women with preeclampsia and gestational hypertension. Study Design: Insulin resistance was measured with the short insulin-tolerance test in 20 women with preeclampsia, in 18 women with gestational hypertension, and in 20 normotensive control subjects. Sex hormone binding globulin, insulin-like growth factor-I, glucose, fructosamine, glycosylated hemoglobin, insulin, C-peptide, and lipids were measured in the fasting state. Results: Women with gestational hypertension had a significant lower insulin sensitivity index (0.13 ± 0.1) and a higher level of insulin-like growth factor-I (333.71 ± 107.6 ng/mL) than women in the control group (0.21 ± 0.1 [P <.05]; 218.11 ± 82.3 ng/mL [P <.01]) and women with preeclampsia (0.21 ± 0.12 [P <.05]; 234.78 ± 92.76 ng/mL [P <.01]). There were no significant correlations between insulin sensitivity index and insulin-like growth factor-I. Conclusion: Insulin resistance is present in women with gestational hypertension but not in women with preeclampsia and did not correlate with insulin-like growth factor-I. (Am J Obstet Gynecol 2002;187:735-40.)

Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass

The concentration of insulin-like growth factor-I (IGF-I) in human cortical bone declines with age, but the relevance of this decline for cortical bone turnover and bone mass is unknown. In the present study, we simultaneously assessed the concentration of IGF-I and -II in cortical bone matrix and histomorphometric parameters of bone mass and bone turnover in 125 samples from the proximal human femur shaft. Bone width decreased by 27% and porosity increased by 100% in female cortical bone between the fourth and the ninth decade. Similar, but weaker, changes tended to occur in male cortical bone. The concentrations of both IGF species were correlated with the percentage of osteons undergoing bone remodeling. However, despite age-related decreases in both IGF species in men and in IGF-I in women, neither of the IGFs accounted for age-related or age-independent variability in cortical porosity or bone width. In conclusion, these data suggest that the local concentrations of IGF-I and -II are related to cortical bone turnover. In contrast, our study provides no evidence for a major role of bone matrix IGF-I and -II as determinants of cortical bone mass in elderly individuals. Whether other components of the IGF system may be stronger determinants of cortical bone loss remains to be determined.

Insulin-Like Growth Factor-I in Women With Hydatidiform Mole and in Normal Pregnancy

Insulin-Like Growth Factor-I in Women With Hydatidiform Mole and in Normal Pregnancy